0000950170-24-066772.txt : 20240530 0000950170-24-066772.hdr.sgml : 20240530 20240530172023 ACCESSION NUMBER: 0000950170-24-066772 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240524 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivic Health Systems, Inc. CENTRAL INDEX KEY: 0001787740 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 814016391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41052 FILM NUMBER: 241006686 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (888)276-6888 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 tivc-20240524.htm 8-K 8-K
0001787740false00017877402024-05-242024-05-24

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2024

 

 

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41052

81-4016391

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

25821 Industrial Blvd.,

Suite 100

 

Hayward, California

 

94545

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TIVC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01 Entry into a Material Definitive Agreement.

On May 21, 2024, Tivic Health Systems, Inc. (the “Company”) entered into a Sublease Termination Agreement (the “Termination Agreement”) with Czarnowski Display Service, Inc. (“CDS”), pursuant to which the parties agreed to terminate that certain Sublease Agreement, by and between the Company and CDS, dated as of November 17, 2021 (the “Sublease”), effective as of May 31, 2024 (the “Termination Date”). The Termination Agreement became effective on May 24, 2024, upon receipt of the master landlord’s written consent to the termination of the Sublease and CDS’ entry into a new sublease agreement with a new sublessee.

 

Under the Sublease, the Company leases approximately 9,091 square feet of office space located at 25821 Industrial Boulevard, Suite 100, Hayward, California (the “Premises”), which serves as the Company's principal place of business. The Sublease was previously scheduled to terminate, in accordance with its terms, on October 31, 2025, unless sooner terminated or cancelled in accordance with the terms and conditions of the Sublease. As of the Termination Date, the Company shall have no further subleasehold or other right, title, or interest in the Premises. In exchange for the early termination of the Sublease pursuant to the Termination Agreement, the Company agreed to make a one-time termination payment to CDS in the amount of $44,480.44. Additionally, in connection with the Sublease, the Company shall pay (i) all commissions owned to any broker in connection with the sublease of the Premises by CDS to the new sublessee, and (ii) any fees or expenses charged by the owner of the Premises in connection with its review of the new sublease agreement with the new sublessee.

 

The Company expects that the termination of the Sublease will result in a reduction of approximately $200,000 in lease expense over the next year and a half.

The foregoing summary of the Termination Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Sublease Termination Agreement, a copy of which is attached to this Current Report on Form 8-K (this "Current Report") as Exhibit 10.1 and is incorporated herein by reference.

 

The Company is currently considering options for the lease of a new premises and principal place of business.

Item 1.02 Termination of a Material Definitive Agreement.

The information set forth in Item 1.01 with respect to the Termination Agreement is incorporated by reference into this Item 1.02.

 

Forward-Looking Statements

This Current Report contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit
No.

Description

10.1

Sublease Termination Agreement, dated May 21, 2024, by and between Tivic Health Systems, Inc. and Czarnowski Display Service, Inc.

104

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TIVIC HEALTH SYSTEMS, INC.

 

 

 

 

Date:

May 30, 2024

By:

/s/ Jennifer Ernst

 

 

 

Name: Jennifer Ernst
Title: Chief Executive Officer

 


EX-10.1 2 tivc-ex10_1.htm EX-10.1 EX-10.1

 

Exhibit 10.1

SUBLEASE TERMINATION AGREEMENT

This Sublease Termination Agreement (this “Agreement”), is dated May 21, 2024 (the “Effective Date”), and is between Czarnowski Display Service, Inc., an Illinois Corporation (“Sublessor”), and Tivic Health Systems, Inc., a Delaware corporation (“Sublessee”).

BACKGROUND

A. Sublessor and Sublessee are parties to a Sublease dated November 17, 2021 (the “Sublease”), covering the real property located at Suite 100, 25821 Industrial Blvd, Hayward, California 94545 commonly known as Building D (the “Premises”).

B. Sublessee has requested that the Sublease be terminated, and Sublessor has agreed to Sublessee’s request to terminate the Sublease as of 5:00 p.m. (Pacific Time) on May 31, 2024 (the “Termination Date”) on the terms and conditions set forth in this Agreement.

Sublessor and Sublessee therefore agree as follows:

1.
Defined Terms. All capitalized terms in this Agreement have the same meaning as in the Sublease unless otherwise defined herein.
2.
Termination. Provided Sublessee timely: (a) pays all Rent and Operating Expenses due under the Sublease through the Termination Date; and (b) surrenders the Premises to Sublessor pursuant to Section 3 below; and (c) pays the Termination Fee required under this Agreement, Sublessor and Sublessee hereby agree that effective as of the Termination Date, the Sublease and the term thereof shall terminate and expire, and Sublessee's leasehold estate in, and right of possession of, the Premises is terminated and wholly extinguished as if the Termination Date was originally set forth in the Sublease as the expiration date thereunder.
3.
Surrender of the Premises.
3.1
On or prior to the Termination Date, Sublessee shall: (i) vacate and deliver possession of the Premises to Sublessor in the condition required on the date of expiration or earlier termination of the Sublease; (ii) remove all its personal property from the Premises; (iii) remove its signage and repair any damage to Building D and the Premises as set forth in Paragraph 15 of the Sublease; and (iv) abandon all leasehold improvements in the Premises (which leasehold improvements Sublessee hereby quitclaims to Sublessor). In the event Sublessee fails for any reason to vacate and surrender possession of all or any part of the Premises to Sublessor on or prior to the Termination Date in accordance with this Agreement, such failure will be deemed a holding over under the Sublease without consent of Sublessor, and Sublessor may exercise all remedies available to Sublessor at law or under the Sublease in connection with such holding over, and Sublessee shall indemnify, defend, and hold Sublessor harmless from all losses, costs (including reasonable attorneys' fees), and liabilities resulting from such failure, including any claims made by any succeeding tenants founded upon such holdover.

 


 

3.2
Any items of personal property remaining on or in the Premises after the Termination Date shall be considered abandoned by Sublessee, and Sublessor shall have the right to dispose of same at Sublessee's sole cost and expense.
3.3
Immediately upon the execution of this Agreement, Sublessor and future occupants of the Premises may have access to the Premises for the purpose of installing tenant improvements and readying the Premises for occupancy.
4.
Release.
4.1
Effective as of the Termination Date, Sublessee, for itself and its respective predecessors-in-interest, successors, and assigns, hereby waives, releases, and forever discharges Sublessor and Lessor, and their respective partners, shareholders, officers, directors, agents, employees, predecessors, successors and assigns (collectively, the “Released Parties”), from all claims, losses, costs, liabilities, damages, expenses (including penalties, fines, and attorneys' fees), warranties, undertakings, agreements, obligations, actions, causes of action, sums of money, covenants, and promises whatsoever in law or in equity (collectively, “Claims”), whether or not now known, suspected, or claimed, that it has had against the Released Parties, now has, or that it or its predecessors-in-interest, successors, or assigns hereafter may have, upon or by reason of any matter, cause, or thing whatsoever arising out of or in connection with the Sublease, the Premises, or the Building.
4.2
Sublessee understands and agrees that it may later discover claims or facts that may be different from, or in addition to, those it now knows or believes to exist regarding the Claims which are the subject of the release contained in subparagraph (a) above, and which, if known at the time of signing this Agreement, may have materially affected this Agreement and Sublessee’s decision to enter into it and grant the release contained in this Agreement. Nevertheless, Sublessee expressly agrees to assume the risk of the possible discovery or existence of such additional or different facts and agree that the release contained in subparagraph (a) above shall be and remain effective in all respects, regardless of such additional or different facts.
4.3
Sublessee understands and agrees, by initialing below, that it expressly waives and relinquishes all rights and benefits, if any, it may have under Section 1542 of the California Civil Code with respect only to the Claims which are the subject of the mutual release set forth in subparagraph (a) above. Section 1542 of the California Civil Code reads as follows:

“§ 1542. [GENERAL RELEASE; EXTENT] A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

___/s/ JE______

2

 


 

Sublessee's initials

5.
Termination Fee. Simultaneously with the execution and delivery of this Agreement by Sublessee and as a condition precedent to the effectiveness of this Agreement, Sublessee shall pay to Sublessor a termination fee in the amount of $44,480.44 (the “Termination Fee”) in consideration for Sublessor's execution and delivery of this Agreement. Sublessor and Sublessee agree that the Termination Fee is nonrefundable, notwithstanding Sublessee's subsequent leasing of the

Premises. Sublessee's payment of the Termination Fee to Sublessor shall be in addition to and shall not be deemed or construed as any payments by Sublessee against, Rent and other costs due from Sublessee under the terms of the Sublease prior to the Termination Date, which Sublessee agrees to pay to Sublessor in accordance with the terms of the Sublease through the Termination Date. The Termination Fee shall be paid by wire transfer, certified check of Sublessor, or bank check drawn on or by a bank, savings and loan association, savings bank, or credit union doing business under California or federal law and delivered to Sublessor at its address provided herein.

6.
Expenses. Sublessee shall pay the following costs in connection with the termination of the Sublease: (a) all commissions owed to any broker in connection with the sublease of the Premises by Sublessor to and OnQ Solutions, Inc., a California corporation (the “New Sublease”) and (b) any fees or expenses charged by the owner of the Premises in connection with its review of the New Sublease.
7.
Representations and Warranties.
7.1
Sublessor and Sublessee each hereby represent and warrant, as of the date hereof and the Termination Date, that: (i) the person executing this Agreement on its behalf is duly authorized to execute and deliver this Agreement on its behalf; and (ii) the execution, delivery, and performance of this Agreement has been duly authorized by all necessary action and does not violate its formation or management documents, or any contract, agreement, commitment, order, judgment, or decree to which it is a party or to which it or the Premises are bound.
7.2
Sublessee hereby represents and warrants, as of the date hereof and the Termination Date, that it has not assigned, sublet, or otherwise transferred or encumbered its interest in the Sublease or the Premises, in whole or in part.
7.3
Sublessee hereby represents and warrants, as of the date hereof and the Termination Date, that it has not dealt with any broker, salesperson, or finder to whom a commission or other fee is due in connection with the Sublease or this Agreement.
7.4
Sublessee hereby represents and warrants, as of the date hereof and the Termination Date, that: (i) there are no contracts let by or on behalf of Sublessee for the furnishing of labor, material, or services for site improvement or a work of improvement in or about the Premises that have not been fully performed; (ii) all parties (if any) who have furnished labor, material, or services upon or to the Premises have been fully paid; (iii) there exists no party who has any right or claim of lien against the Premises for having

3

 


 

furnished labor, material, or services thereon; and (iv) there are no mechanics liens, claims of mechanics lien, or right to mechanics liens in the Premises arising out of any act or omission of Sublessee.
8.
Indemnification. Sublessor and Sublessee each agree to indemnify, hold harmless, and defend the other party from and against any and all claims, liabilities, losses, costs, damages, and expenses (including reasonable attorneys' fees, charges, and expenses in the enforcement of this indemnity) asserted against or suffered by the other party arising out of, related to, or caused by the breach or inaccuracy of any covenant, obligation, warranty, or representation under this Agreement by the other party. This Section 8 shall survive the termination of the Sublease.
9.
Security Deposit. The Security Deposit under the Sublease, in the amount of $33,500, shall be retained by Sublessor and applied to the balance of the Termination Fee.
10.
Further Assurances. Sublessor and Sublessee each agree to promptly execute, acknowledge, and deliver to the other such further instruments and take such further actions as may be reasonably required to carry out and effectuate the intent and purpose of this Agreement.
11.
Governing Law. This Agreement shall be governed by, interpreted under, and construed and enforced in accordance with the laws of the State of California.
12.
Severability. If any term or provision of this Agreement is held by a court to be invalid, illegal, or unenforceable, such invalidity, illegality, or unenforceability shall not affect, invalidate, or render unenforceable any other term or provision of this Agreement. [Upon such determination that any term or other provision is invalid, illegal, or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the greatest extent possible.]
13.
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same document. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or email in an electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement.
14.
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of Sublessor and Sublessee and their respective successors and assigns.
15.
Entire Agreement; No Oral Modification. This Agreement constitutes the entire understanding between the parties, and supersedes all other prior agreements, discussions, understandings, offers, and negotiations, written or oral, between the parties, with respect to the Sublease, the leasehold estate created thereby, and the termination thereof. No provision hereof may be waived, modified, amended, discharged, or terminated except by written instrument signed by all the parties to this Agreement.
16.
Confidentiality. Sublessee shall keep the terms of this Agreement confidential and shall not disclose the terms of same to any other party without the prior written consent of Sublessor, provided that Sublessee may disclose the terms hereof to Sublessee's accountants, attorneys,

4

 


 

managing employees, and others in privity with any such party to the extent reasonably necessary for Sublessee’s business purposes or if required by court order.
17.
No Recording. Sublessee shall not record this Agreement or any memorandum or short form of this Agreement without the prior written consent of Sublessor.
18.
Legal Fees. In any dispute involving the enforcement of this Agreement, the non-prevailing party in such dispute shall pay all costs and expenses, including but not limited to reasonable attorneys' fees, incurred by the party prevailing in such dispute.
19.
Time of the Essence. Time is of the essence with respect to each and every term, condition, obligation, and provision of this Agreement.

[signature page follows]

 

5

 


 

Sublessor and Sublessee have caused this Agreement to be executed as of the Effective Date.

 

SUBLESSOR:

Czarnowski Display Service, Inc.

By: Jason Barnes

Name: Jason Barnes

Title: CFO

 

 

SUBLESSEE:

Tivic Health Systems, Inc.

By: Jennifer Ernst

Name: Jennifer Ernst

Title: CEO

 

 

 

6

 


EX-101.SCH 3 tivc-20240524.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 24, 2024
Entity Registrant Name Tivic Health Systems, Inc.
Entity Central Index Key 0001787740
Entity Emerging Growth Company true
Entity File Number 001-41052
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-4016391
Entity Address, Address Line One 25821 Industrial Blvd.,
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 888
Local Phone Number 276-6888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TIVC
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tivc-20240524.htm tivc-20240524.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tivc-20240524.htm": { "nsprefix": "tivc", "nsuri": "http://www.tivichealthsystems.com/20240524", "dts": { "inline": { "local": [ "tivc-20240524.htm" ] }, "schema": { "local": [ "tivc-20240524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_0744fdaa-4e39-4e2f-9990-859eaabc8083", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240524.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0744fdaa-4e39-4e2f-9990-859eaabc8083", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240524.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.tivichealthsystems.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-066772-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-066772-xbrl.zip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end XML 15 tivc-20240524_htm.xml IDEA: XBRL DOCUMENT 0001787740 2024-05-24 2024-05-24 0001787740 false 8-K 2024-05-24 Tivic Health Systems, Inc. DE 001-41052 81-4016391 25821 Industrial Blvd., Suite 100 Hayward CA 94545 888 276-6888 false false false false Common Stock, par value $0.0001 per share TIVC NASDAQ true false